Expertise in
7
conditions

Marc G. Berger

Clermont-ferrand, FR 
Expertise in
7
conditions
Clermont-ferrand, FR 
OverviewLocationsClinical Research

Overview

Marc Berger practices in Clermont-ferrand, France. Mr. Berger is highly rated in 7 conditions, according to our data. His top areas of expertise are Gaucher Disease Type 1, Chronic Myelogenous Leukemia (CML), Gaucher Disease, Splenomegaly, and Splenectomy.

His clinical research consists of co-authoring 86 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Clermont-ferrand, France
Other Locations
Lyon, France
Saint-etienne-de-valoux, France
Bordeaux, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Multicentre, Open-label Phase II Trial Evaluating the Safety and Efficacy of Ponatinib Induction Followed by Imatinib Maintenance in Adult Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) ≤ 65 Years
A Multicentre, Open-label Phase II Trial Evaluating the Safety and Efficacy of Ponatinib Induction Followed by Imatinib Maintenance in Adult Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) ≤ 65 Years
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib
Study Phase: Phase 2
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Enrollment Status: Completed
Publish Date: August 18, 2022
Intervention Type: Drug
Study Drug: Nilotinib
Study Phase: Phase 2
The COMETE Network, Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card
The COMETE Network, Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card
Enrollment Status: Completed
Publish Date: September 24, 2019
Intervention Type: Biological
Study Phase: Not Applicable
Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: A Pilot Diagnostic Accuracy Study
Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: A Pilot Diagnostic Accuracy Study
Enrollment Status: Completed
Publish Date: September 25, 2018
Intervention Type: Diagnostic test
View 3 Less Clinical Trials

86 Total Publications

Imatinib-Induced Reactive Angioendotheliomatosis: A Paradoxical Pro-Angiogenic Case.
Imatinib-Induced Reactive Angioendotheliomatosis: A Paradoxical Pro-Angiogenic Case.
Journal: International journal of dermatology
Published: July 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Berger's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile